This Article Full Text (PDF) All Versions of this Article: 1756283X09339079v1 2/5/287    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Navaneethan, U. Articles by Neff, G. W. Social Bookmarking                         What's this?

Review: Predicting the probable outcome of treatment in HCV patients

Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA, guy.neff{at}uc.edu

Nyingi Kemmer

Udayakumar Navaneethan Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA

Guy W. Neff

Nyingi Kemmer, MD, MBA Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA

Hepatitis C virus (HCV) is a major cause of chronic liver disease infecting more than 170 million people worldwide. HCV produces a wide gamut of manifestations varying from mild self-limiting disease to cirrhosis and hepatocellular carcinoma. A variety of viral, environmental and host genetic factors contribute to the clinical spectrum of patients infected with HCV and influence response to interferon (IFN) therapy. Predicting the probable outcome of treatment in patients with HCV infection has always been a challenging task. Treatment of HCV by pegylated interferon (peg-IFN) plus ribavirin eradicates the virus in approximately 60% of patients — HCV genotype 1 (42—51% response rates) and genotypes 2 and 3 (76—84% response rates); however, a significant number of patients do not respond to therapy or relapse following discontinuation of treatment or have significant side effects that preclude further treatment. Accurately predicting the patients who will respond to therapy is becoming increasingly important, both from the point of patient care and also with respect to the healthcare cost as clinicians need to continue treatment in patients who will respond and stop treatment in patients who are unlikely to respond. Viral RNA measurements and genotyping are used to optimize treatment as a low viral load and nongenotype 1 is more likely to be associated with sustained virological response (SVR). Rapid virological response (RVR) defined by undetectable HCV RNA at 4 weeks of treatment is increasingly being recognized as a powerful tool for predicting treatment response. A variety of host factors including single nuclear polymorphisms (SNPs) of IFN response genes, insulin resistance, obesity, ethnicity, human leukocyte antigens and difference in T-cell immune response has been found to modulate the response to antiviral treatment. The presence of severe fibrosis/cirrhosis on pretreatment liver biopsy predicts a poor response to treatment. Recent studies on gene expression profiling and characterization of the liver and serum proteome provide options to accurately predict the outcome of patients infected with HCV in the future. Future studies on the factors that predict treatment response and tailoring treatment based on this is required if we are to conquer this disease.

Key Words: hepatitis C • pegylated interferon • ribavirin • predicting outcome • sustained virological response

This version was published on September 1, 2009

Therapeutic Advances in Gastroenterology, Vol. 2, No. 5, 287-302 (2009)
DOI: 10.1177/1756283X09339079


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?